Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Ovid Therapeutics

Ovid Therapeutics

A biotechnology company specializing in creating therapeutics for neurological disorders. It was founded in 2014 and is located in New York City.

About

Ovid Therapeutics is a New York-based company with a focus on developing medicines for patients living with rare neurological disorders. The company partners with patient advocacy groups and foundations in order to better understand the community for whom it is working.It also collaborates with other biotechnology and pharmaceutical companies to develop its therapeutics, such as Takeda and Lundbeck.

Product

The company has multiple therapeutics that are in the process of going through clinical trials. It focuses on specific neurological disorders and develops drugs to treat those disorders. One such disorder is Angelman syndrome. The company is conducting clinical trials for both adolescents and adults for therapeutics such as gaboxadol.

FAnother disorder for which the company is developing therapeutics is Fragile X syndrome. The clinical trials also used the therapeutic gaboxadol. The studies for CDKL5 deficiency disorder and chromosome 15q duplication syndrome used the therapeutic soticlestat to seek results.

Timeline

August 2020
The University of Connecticut partners with Ovid Therapeutics for rare-disease research.
August 2020
Ovid Therapeutics partners with Angelini for research.
January 23, 2017
Ovid Therapeutics raises a $25,861,228 series C round.
August 11, 2015
Ovid Therapeutics raises a $75,000,000 series B round from Cormorant Asset Management, Jennison Associates, Redmile Group, Sanofi Ventures, Sphera Funds Management and Tekla Capital Management.
March 16, 2015
Ovid Therapeutics raises a $5,100,000 venture round.
2014
Ovid Therapeutics is founded.

Funding Rounds

Patents

Further Resources

Title
Author
Link
Type
Date

News

Title
Author
Date
Publisher
Description
Mark Terry
July 9, 2021
BioSpace
BioSpace's Pharm Country Hotbed ranges from Connecticut, New York, New Jersey, Pennsylvania and Rhode Island.
Annalee Armstrong
July 9, 2021
FierceBiotech
After Ovid Therapeutics' lead product failed a phase 3 clinical trial in April, CEO Jeremy Levin knew they had some tough work ahead of them. Now, the biotech has announced a leadership shuffle and staff reductions as it pivots to focus on early-stage development. One thing remains the same: Ovid will still focus on neurosciences.
Alex Keown
June 11, 2021
BioSpace
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Annalee Armstrong
April 22, 2021
FierceBiotech
Ovid Therapeutics CEO Jeremy Levin had a difficult choice to make in shedding the company's lead Angelman syndrome asset OV101, but a recent deal with Takeda at least took financing out of the equation.
Amirah Al Idrus
April 19, 2021
FierceBiotech
Just weeks after handing full control of its Takeda-partnered epilepsy program back to the Japanese pharma, Ovid Therapeutics is pulling the plug on its lead program, OV101, a treatment that was under development for Angelman syndrome and Fragile X syndrome. Now, the company's focus turns to its earlier-stage pipeline.
SHOW MORE

References

Golden logo
By using this site, you agree to our Terms & Conditions.